ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
Tuesday, July 5, 2011 - 09:31
in Health & Medicine
ALK rearrangement has been found in 9.6 percent of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1 percent, reflecting how many patients might benefit from targeted therapies such as crizotinib, according to new research.